- ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
- ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
- ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
- ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
- ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
- ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
- ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
- ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
- ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
More ▼
Key statistics
On Thursday, Zyversa Therapeutics Inc (ZVSA:NAQ) closed at 4.86, 9.46% above its 52-week low of 4.44, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.90 |
---|---|
High | 4.99 |
Low | 4.83 |
Bid | 4.87 |
Offer | 5.15 |
Previous close | 4.94 |
Average volume | 165.86k |
---|---|
Shares outstanding | 759.49k |
Free float | 753.19k |
P/E (TTM) | -- |
Market cap | 3.75m USD |
EPS (TTM) | -1,922.89 USD |
Data delayed at least 15 minutes, as of May 16 2024 21:00 BST.
More ▼